Therapeutic Applications: Natural Killer Cells

被引：0

作者：

Sharma, Preeti ^{[1
]}

Kumar, Pradeep ^{[1
]}

Sharma, Rachna ^{[2
]}

机构：

[1] Santosh Med Univ, Dept Biochem, Ghaziabad, Uttar Pradesh, India

[2] Santosh Med Univ, Dept Biochem, Lucknow, Uttar Pradesh, India

来源：

JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH | 2018年 / 12卷 / 02期

关键词：

Adoptive immunotherapy; Chimeric antigen receptor; Immunosurveillance;

D O I：

10.7860/JCDR/2018/29970.11187

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Natural Killer (NK) cells are potent cytotoxic effector cells for cancer therapy and also for keeping severe viral infections in check. Since, they represent only 10% of the lymphocytes and are often dysfunctional, there are technical challenges in obtaining sufficient numbers of functionally active NK cells from a patient's blood. Recent advances in therapeutic regimen of NK cells are intended to enhance NK cell activity and targeting strategies. With recent advances in the field of NK cell biology and translational research, it seems that over the next few years, NK cell immunotherapy will move to the forefront of cancer immunotherapy. The current review focuses on recent developments in NK cell immunotherapy including various approaches i.e. augmentation of Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), manipulation of receptor-mediated activation, and adoptive immunotherapy with ex vivo-expanded NK cells, Chimeric Antigen Receptor (CAR)-engineered, or engager-modified NK cells.

引用

页码：BE1 / BE3

页数：3

共 27 条

[1] CAR models: next-generation CAR modifications for enhanced T-cell function [J].

Abate-Daga, Daniel ;

Davila, Marco L. .

MOLECULAR THERAPY-ONCOLYTICS, 2016, 3 :16014

[2] CAR T Cell Therapy: A Game Changer in Cancer Treatment [J].

Almasbak, Hilde ;

Aarvak, Tanja ;

Vemuri, Mohan C. .

JOURNAL OF IMMUNOLOGY RESEARCH, 2016, 2016

[3]

Bachanova Veronika, 2014, Critical Reviews in Oncogenesis, V19, P133

[4] Molecular mechanisms of natural killer cell activation in response to cellular stress [J].

Chan, C. J. ;

Smyth, M. J. ;

Martinet, L. .

CELL DEATH AND DIFFERENTIATION, 2014, 21 (01) :5-14

[5] GD2-Targeted Immunotherapy and Radioimmunotherapy [J].

Dobrenkov, Konstantin ;

Cheung, Nai-Kong V. .

SEMINARS IN ONCOLOGY, 2014, 41 (05) :589-612

[6] Design and development of therapies using chimeric antigen receptor-expressing T cells [J].

Dotti, Gianpietro ;

Gottschalk, Stephen ;

Savoldo, Barbara ;

Brenner, Malcolm K. .

IMMUNOLOGICAL REVIEWS, 2014, 257 (01) :107-126

[7] Human natural killer cell development and biology [J].

Farag, Sherif S. ;

Caligiuri, Michael A. .

BLOOD REVIEWS, 2006, 20 (03) :123-137

[8]

Farhan S, 2012, IMMUNOTHERAPY-UK, V4, P305, DOI [10.2217/imt.11.174, 10.2217/IMT.11.174]

[9] The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT) [J].

Foley, Bree ;

Felices, Martin ;

Cichocki, Frank ;

Cooley, Sarah ;

Verneris, Michael R. ;

Miller, Jeffrey S. .

IMMUNOLOGICAL REVIEWS, 2014, 258 (01) :45-63

[10] Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production [J].

Gleason, Michelle K. ;

Verneris, Michael R. ;

Todhunter, Deborah A. ;

Zhang, Bin ;

McCullar, Valarie ;

Zhou, Sophia X. ;

Panoskaltsis-Mortari, Angela ;

Weiner, Louis M. ;

Vallera, Daniel A. ;

Miller, Jeffrey S. .

MOLECULAR CANCER THERAPEUTICS, 2012, 11 (12) :2674-2684

← 1 2 3 →